Analyst firms · Barclays · BAX
Barclays BAX price target and rating history
Baxter International Inc. (BAX) · Health Care
Barclays rates Baxter International Inc. (BAX) Underweight with a $20 price target, as of its latest action on Oct 7, 2026. It has published 4 rating actions on BAX since September 2021, including 1 upgrade and 0 downgrades.
- Current rating
- Underweight
- Price target
- $20
- Median target, all firms
- Too few
- Actions on BAX
- 4
Barclays price target on BAX
Every Barclays rating on BAX
- Oct 7, 2026
- Feb 20, 2025
- Oct 18, 2022
- Sep 3, 2021
How other firms rate BAX
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Peer Perform | Oct 20, 2026 | |
| Barclays | Underweight | $20 | Oct 7, 2026 |
| Citigroup | Neutral | $28 | Jul 31, 2026 |
Questions about Barclays and BAX
- What is Barclays's price target for BAX?
- Barclays's latest stated price target for Baxter International Inc. (BAX) is $20, from its action on Oct 7, 2026.
- What is Barclays's rating on BAX?
- Barclays rates BAX Underweight, a bearish rating, as of Oct 7, 2026.
- When did Barclays last change its view on BAX?
- On Oct 7, 2026, Barclays starts coverage at Underweight, price target $20.
More BAX rating histories
All Barclays ratingsBAX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.